



May 13, 2025

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**BSE Limited**

P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
Mumbai - 400 001

**Symbol: LUPIN**

**Scrip Code: Equity - 500257**

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

*Dear Sir/Madam,*

We are pleased to enclose a Press Release as regards, launch of Tolvaptan Tablets, 15 mg, 30 mg, 45 mg, 60 mg and 90 mg, in the United States, following the recent approval received from the U.S. FDA.

The same is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**AMIT KUMAR GUPTA  
COMPANY SECRETARY & COMPLIANCE OFFICER  
(ACS -15754)**

**Encl: a/a.**

LUPIN LIMITED

**Registered Office:** 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin Launches Tolvaptan Tablets in the U.S. with 180-Day Exclusivity

**Mumbai, Naples, May 13, 2025:** Following the recent approval received from the United States Food and Drug Administration (U.S. FDA), global pharma major Lupin Limited (Lupin) today announced the launch of Tolvaptan Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg in the United States. Lupin holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity.

Tolvaptan Tablets are bioequivalent to Jynarque® Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company, Ltd., and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

"We are pleased to announce the launch of Tolvaptan Tablets in the U.S. to provide ADPKD patients with increased access to high-quality treatment options," said **Vinita Gupta, CEO, Lupin.**

Tolvaptan Tablets (RLD Jynarque®) had an estimated annual sale of USD 1,467 million in the U.S. (fiscal year ended December 31, 2024).

### About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit [www.lupin.com](http://www.lupin.com) or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

**For further information or queries please contact –**

### Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin  
[rajalakshmiazariah@lupin.com](mailto:rajalakshmiazariah@lupin.com)

### **\*Safe Harbor Statement**

Jynarque® is the registered trademark of Otsuka Pharmaceutical Company Ltd.